Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bria-IMT + retifanlimab
- Development stage
- Unknown
- Lead developer
- BriaCell Therapeutics
- Modality
- Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
Bria-IMT + retifanlimab is a combination therapy under investigation for advanced and metastatic breast cancer. The regimen consists of Bria-IMT (SV-BR-1-GM), an off-the-shelf, targeted cell-based immunotherapy developed from a genetically engineered human breast cancer cell line that secretes granulocyte-macrophage colony-stimulating factor (GM-CSF), combined with retifanlimab, a monoclonal antibody immune checkpoint inhibitor targeting programmed death receptor 1 (PD-1). This combination aims to enhance anti-tumor immune responses by both stimulating the immune system against tumor antigens and blocking PD-1-mediated immunosuppression. Clinical trials have shown promising results in heavily pretreated hormone receptor-positive and other subtypes of metastatic breast cancer, including patients with central nervous system metastases. The therapy has demonstrated favorable safety and tolerability profiles as well as improved overall survival compared to historical controls[1][4][5][6][7].
- Other names
- Bria-IMT regimen plus checkpoint inhibitorBria-IMT combination regimen
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on Bria-IMT + retifanlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bria-IMT + retifanlimab.